Biogen
Manufacturing · Massachusetts, United States · 5K - 10K Employees
View Company Info for Free
Overview
Headquarters
225 Binney St, Cambridge, Massachusetts,...Phone Number
(781) 464-2000Website
www.biogen.comRevenue
$10 BillionStock Symbol
BIIBIndustry
ZI Rank: 1
Signal Type
Feb
Mar
Apr
May
Jun
Jul
ZI Rank
1
3
3
2
2
1
About Biogen
Biogen is a U.S.-based biotechnology company focused on discovering, developing, and commercializing therapies for serious neurological and neurodegenerative diseases. Its core portfolio includes treatments for conditions such as multiple sclerosis, spinal muscular atrophy, and other rare neurological disorders, supported by advanced research in neuroscience, biologics, and gene-based therapies.Explore more
Biogen Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Biogen your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check if Biogen has recently received funding, and reach out quickly before it becomes old news!
Earning: See what the market has to say on Biogen recently announced quarterly report
Website visits: Recent activity has been detected on your website
Click to see if Biogen had a recent Job posting/layoffs
Biogen, which may be a good buyer, showed buying intent in Masked Content Topic
Congratulate Masked Content for being promoted to Masked Content at Biogen
Product Launch: Get notified when Biogen launches new products
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Funding: Get notified immidiatlly once Biogen has new funding data
Check out if Biogen is spiking on competitors!
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find more new buyers
Compare Similar Companies to Biogen
Compare insights from companies similar to Biogen, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
$29.7B
10K+
Public
$296.3M
1987
CD
Courtney DesmondChief of Staff To Senior Vice President Chief Ethics and Compliance Officer
Company Profile Activity
Activity Insights
Biogen is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Biogen is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Biogen.
Biogen Tech Stack
A closer look at the technologies used by Biogen
Most Recent Scoops
New Hire
Executive Move
Executive Moves, New Hire
Project
Biogen has reported that in Japan and Europe, particularly Germany, Spinraza high dose is driving a reversal of the trend of patients switching to oral therapy, with patients trending back to Spinraza.
Implementation, Pharmaceuticals
Earnings
Biogen has reported that it expects approximately $0.85 of non-GAAP EPS dilution in 2026 primarily from financing costs associated with the Apellis transaction, with the transaction expected to be accretive to non-GAAP diluted EPS in 2027.
Earnings, Finance, Financing & Debt
Product Launch
Biogen has announced an expected prefilled syringe launch for Ciphovri, designed to support physician workflow by saving approximately 15 minutes per injection.
Product Launch, Pharmaceuticals
Project
Pharmaceuticals, Clinical Operations
Biogen News & Media
LEQEMBI IQLIK® (lecanemab-irmb) Autoinjector for Initiation of Therapy Now Available in the U.S. for Early Alzheimer’s Disease
LEQEMBI IQLIK is the first-of-its-kind anti-amyloid treatment worldwide offering at-home dosing for initiation and maintenance (approved in the U.S.) LEQEMBI IQLIK is the first-of-its-kind anti-amyloid treatment worldwide offering at-home dosing for initiation and maintenance (approved in the U.S.)Biogen, Investors Reach Settlement Outline Over Alzheimer's Drug - Bloomberg Law
Biogen Inc. has roughed out a settlement agreement with investors in a proposed class action alleging the company misrepresented clinical trial data for its Alzheimer’s drug Aduhelm, according to a federal court filing.Biogen Completes Acquisition of RayThera Inc.
Lead program now in Phase 1 development Lead program now in Phase 1 developmentBiogen shifts M&A strategy as Apellis acquisition pushes revenue above analyst expectations
Biogen officially began reporting revenue from the $5.6 billion acquisition of Apellis in the second quarter, shaking up analysts’ consensus estimates and leading to a beat.
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Biogen
Sign Up For FreeTo access detailed company insights
Biogen is a U.S.-based biotechnology company focused on discovering, developing, and commercializing therapies for serious neurological and neurodegenerative diseases. Its core portfolio includes treatments for conditions such as multiple sclerosis, spinal muscular atrophy, and other rare neurological disorders, supported by advanced research in ne... Read More
